European Commission approve Odomzo (formerly LDE225)

Last Updated on Wednesday, 03 February 2016 14:09
Published on Tuesday, 08 September 2015 13:42
Hits: 7963

Novartis announce approval of Odomzo (formerly LDE225).

The treatment is for adult patients with locally advanced basal cell carcinomas, who are not amenable to curative surgery.

Reinherd Dummer, MD, Professor and Vicechairman, Department of Dermatology at the University of Zurich quotes "The approval of Odomzo brings new hope in the form of a non-invasive option to help treat this disfiguring and potentially life-threatening disease. 

For further information about the treatment go to Novartis announcement.